Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sanbio Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are distributed among 3 distinct examiners and 3 distinct art units. This means every action is being handled by a different examiner in a different art unit. DRISCOLL, LORA E BARNHART is the busiest examiner, responsible for 1 pending office action.
This accounts for a portion of the total pending workload. The fact that there are 3 distinct art units for 3 pending office actions indicates a high degree of technical dispersion. Each of the 3 pending office actions represents a unique combination of examiner and art unit for the company. This distribution requires the company to manage three separate examiner relationships across three different specialized groups within the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (33%) |
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, LORA E BARNHART | 1 | 31.8% | +20.8% |
| LANKFORD JR, LEON B | 1 | 70.0% | +31.5% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605731 | METHODS AND COMPOSITIONS FOR MODULATING DOPAMINERGIC NEURONS | SCHUBERG, LAURA J | 84d |
| 19293815 | NEURAL REGENERATING CELLS WITH ALTERATIONS IN DNA METHYLATION | DRISCOLL, LORA E BARNHART | — |
| 18887839 | CELL THERAPIES AND METHODS OF TREATMENT FOR SMALL-VOLUME STROKE | LANKFORD JR, LEON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605731 | METHODS AND COMPOSITIONS FOR MODULATING DOPAMINERGIC NEURONS | SCHUBERG, LAURA J | 84d |
| 19293815 | NEURAL REGENERATING CELLS WITH ALTERATIONS IN DNA METHYLATION | DRISCOLL, LORA E BARNHART | — |
| 18887839 | CELL THERAPIES AND METHODS OF TREATMENT FOR SMALL-VOLUME STROKE | LANKFORD JR, LEON B | — |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| 1657 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19293815 | NEURAL REGENERATING CELLS WITH ALTERATIONS IN DNA METHYLATION | DRISCOLL, LORA E BARNHART | 3991 | §101Other | Non-Final OA | — | Pending | Aug 07, 2025 |
| 18887839 | CELL THERAPIES AND METHODS OF TREATMENT FOR SMALL-VOLUME STROKE | LANKFORD JR, LEON B | 1657 | §101§103Other | Non-Final OA | — | Pending | Sep 17, 2024 |
| 18605731 | METHODS AND COMPOSITIONS FOR MODULATING DOPAMINERGIC NEURONS | SCHUBERG, LAURA J | 1631 | §103§112 | Final Rejection | 84d | Pending | Mar 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSanbio Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Lora E Barnhart Driscoll has the most, with 1 of Sanbio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
